Greetings, and welcome to P3 Health Partners' Third Quarter 2022 Earnings Conference Call. At this time, all participants are in listen only mode. A brief Q&A session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Karen Blomquist. Please go ahead. Thank you, operator, and thank you for joining us today. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under the U.S. federal securities laws, including statements regarding our financial outlook and long-term targets. These forward-looking statements are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from the statements made on this call is contained in our periodic reports filed with the SEC. The forward-looking statements made during this call only as of the date hereof, and the company takes no obligation to update or revise these forward-looking statements. We will refer to certain non-GAAP financial measures on this call. These non-GAAP financial measures are in addition to and not a substitute or superior to measures of financial performance prepared in accordance with GAAP. There are a number of limitations related to the use of these non-GAAP financial measures. For example, other companies may calculate similarly titled non-GAAP financial measures differently. Refer to the appendix of our earnings release for reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures. Information presented on this call is contained in the press release we issued today and in our SEC filings, which may be accessed from the investor relations page of the P3 Health Partners website. I will now turn the call over to Dr. Sherif Abdou. Thanks, Karen. Good afternoon, everyone, and thank you for joining us in our call today. I know it's only been a few weeks since our last update, and as promised, we are now back on a normal cadence of earning releases. I'd like to start by providing a snapshot of the results and the strong demand as we see for our value-based care. I will then turn the call over to Erin Darakjian, our Interim CFO, for the financial review. Finally, we'll turn it over to Dr. Amir Bacchus, our Chief Medical Officer and Co-founder, who will provide some insight into P3 through the lens of the physicians. I will just start by saying we had a strong third quarter with a strong underlying performance. Our membership is up 67% from the third quarter last year. In the third quarter, we achieved nearly 60% increase in revenue compared to the prior year. We had roughly 180 basis point improvement in gross margin in the first nine months of 2022 compared to the same period in the prior year. Our EBITDA per member per month improved 6.5% approximately in the Q3 of 2022 comparing to a prior year. Our base cohort on our platform for 36+ months continue to improve and achieve an average of annual 11% improvement in medical cost. We are seeing consistent improvement in our medical margin, which is capitated revenue minus medical expense. We are also anticipating a robust pipeline for 2023. We believe that our growth in 2022 continues to demonstrate that our vision to be a leader of transformational health care with our patient-centered, outcome-oriented care model is succeeding. In more and more markets across the country, growth in the value-based care model has not only gained traction, but is proving its relevance with nearly 50% of Medicare population now on Medicare Advantage. At P3, we are succeeding by engaging the patients, the providers, and the payers in the singular goal of achieving better clinical outcome while at the same time lowering the cost of care. Let me highlight a few examples of how we are leveraging the value-based care model to make exciting steps on this important journey to transform healthcare. The fee-for-service model historically has incentivized the excess utilization of high acuity services. P3 and our physician-led leadership understand the disconnect that ultimately leads to poorer, more costly care for the patients and to physician burnout. That is why it is critical that we shift that paradigm to the benefit of our patients, the providers, and to lower the overall cost of care. We know that we must rewrite the social and moral contract between physician and patient. The value-based model removes the pressure on primary care physicians to operate in high volume environment, which is frequently characterized by overpacked schedule with limited opportunity to fully engage with the patient to assess their overall health, life circumstances, and social determinants of health, which may affect their care and their clinical outcome as well. Value-based care replaces volume-based care with the teams, tools, and technologies to align the social, moral, and economic incentive between providers, patients, and payers. Our integrated clinical review technology solution enables provider to get a 360-degree view of the patients so that they have the right insights around the patient's potential medical condition at the point of care during the patient visit. In our model, the physician, the patient, and the payer all benefit from the patient's better clinical outcome. As you may have seen in Q3 earnings press release, today, we are changing our Adjusted EBITDA guidance. As always, I wanted to provide transparency and clarity for you as our shareholders. First, as a result of the length of the 2021 audit, we had to shift some revenue that would typically have been reflected in the current year back into the prior year. Second, the cost of 2021 audit and restatement process were sizable and impacted 2022 EBITDA. Third, we have been assessing the impact of the 2021 audit on 2022, and Erin will provide more clarity around this. As I said, Erin will provide more clarity on those drivers and a change in guidance. I wanted to stress this change is not the result of the underlying performance of the company. I am very excited about the future of P3, and you should be as well. Our expectations for 2023 as we roll out of this transformative year. The robust pipeline we see will be balanced with purposeful and disciplined growth. We are taking measured steps to grow at the right pace to support the health of the business to ensure we succeed in our mission to lead the transformation of healthcare. With that, I will now turn over to Erin Darakjian for review of our financial results and other business development. Erin? Thank you, Sherif. Our Q3 2022 top line growth remains strong with total revenue of $248 million, a $92 million or a 59% increase over the same period in the prior year. For the three months ended September 30th, 2022, we reported a net loss of $65 million compared to a net loss of $32 million in the three months ended September 30th, 2021. The increase in the loss was primarily driven by onboarding roughly 35,000 new patients to our platform during 2022, which included adding new employees to support that growth, as well as non-recurring costs related to consulting fees. Adjusted EBITDA loss, a non-GAAP measure, was $40 million in Q3 2022, compared to an Adjusted EBITDA loss of $26 million in the same period of the prior year. On a per member per month basis, Adjusted EBITDA loss in Q3 was $133, an improvement over a loss of $142 PMPM in the prior year. Our Q3 2022 year to date top line growth remains strong with total revenue of $791 million, a $339 million or 75% increase over the same period in the prior year. 99% of that revenue was derived from capitated agreements related to our at-risk Medicare Advantage members. For the first nine months of 2022, we reported a net loss of $1 billion compared to a net loss of $86 million in the nine months of the prior year. The increase in the loss was primarily driven by goodwill impairment charge, which increased the net loss by $852 million. The impairment charge was taken due to the decrease in our market cap relative to the book value of goodwill. This was a non-cash charge to our income statement during the period. Excluding the impairment charge, our net loss reflects the ramp-up cost associated with onboarding roughly 35,000 new patients to our platform during 2022, including the addition of staff to support that growth as well as consulting fees. Adjusted EBITDA loss, a non-GAAP measure, was $88 million in Q3 2022 year to date, compared to an Adjusted EBITDA loss of $60 million in the same period of the prior year. On a per member per month basis, Adjusted EBITDA loss year to date 2022 was $97, an improvement over a loss of $110 PMPM in the prior year, which reflects the power of our model to drive down costs. We ended the third quarter 2022 with unrestricted cash and cash equivalents of approximately $34 million. As we said previously on our last call, we expect 2023 cash burn to be more modest than in 2022, given maturation of our members and lower growth more consistent with our long-term projections. We are actively working with outside advisors to raise sufficient capital in the debt and/or equity market to reach profitability and self-sustaining cash flow in 2024. The use of cash reflects the investment required to support our strong growth and investments in building the infrastructure and professional staff needed to meet our obligations as a public company. Our receivables have increased by $36 million in the third quarter of 2022 over the same period in the prior year, reflecting the strong growth in our business. We are very focused on near-term expense control while onboarding our new patients to our care model so that we can realize Adjusted EBITDA profitability by 2024, as referenced in our previous guidance. For the full year 2022, we are reiterating the revenue guidance we gave on our second quarter call and expect revenue to range between $1.025 billion-$1.075 billion, representing a 61%-69% increase over 2021. We expect at-risk Medicare Advantage members to be greater than 100,000 at December 31st, 2022, representing a roughly 35% increase over prior year. As Sherif mentioned, we are updating our full year guidance for Adjusted EBITDA to a loss between $118 million-$128 million compared to the prior guidance loss between $55 million-$90 million. I'd like to provide you with some detail around the change. First, due to the 2021 audit being open until October 21st, we recognized $12 million related to the 2021 final sweeps or settlement in 2021, which otherwise would have been recognized in 2022. Second, due to the length of the 2021 audit and the resources necessary to complete the audit, including audit firms, financial consultants, and legal firms, we incurred non-recurring costs of approximately $7 million-$10 million. Third, in assessing the 2021's audit impact on 2022, we considered applying the same treatment to the final 2022 sweeps to be consistent with the treatment of the final 2021 sweep. However, after discussions with our auditors and consultants, we have decided not to change our revenue recognition policy. Therefore, we will recognize the revenue of the final 2022 sweeps when received in 2023. This results in $15-$20 million in revenues and Adjusted EBITDA from 2022 being recognized in 2023. In summary, our full year Adjusted EBITDA guidance of - $118-$128 million excludes approximately $12 million in profits moved to 2021 and does not include an incremental $15-$20 million in revenue, which would be captured by the 2022 final sweeps and which are attributed to 2022 and prior years. The updated guidance also reflects $7-$10 million in non-recurring costs related to our extended financial close and the restatement process. As we think about our Adjusted EBITDA guidance, if not for these adjustments, our 2022 Adjusted EBITDA guidance loss would be an improvement of between $34 million and $42 million. On a per member per month basis, we are updating our full year 2022 Adjusted EBITDA loss outlook to reflect the changes I just mentioned. As a result, we are now at the loss between $97 and $107 per member per month. This compares to our prior guidance of a loss of $45-$75 per member per month, an improvement of 11%-22% over a loss of $119 at the end of 2021. With that, I'll turn the call over to Dr. Bacchus to give you an example of P3 in action. Thank you, Erin. At P3, our model is focused on engagement, whether with our payers through delegation, our patients through care management and thoughtful communication, or our providers through direct interaction via both our clinical and administrative teams. Today, I'd like to shed some light on how we work with providers by describing a recent interview from a large provider practice in our Oregon network. Dr. Tim Powell, CEO of Evergreen Family Medicine, highlighted some of the benefits of P3 in his recent YouTube interview. Dr. Powell shared his view on the benefits of having P3 for his patients, and he described P3 through a couple of short stories that show how P3 supports provider groups. His first example described an elderly patient in his care who had suffered from a disabling stroke many years earlier that left one side of his body paralyzed. The patient's wife had been taking care of him for about 10 years, and now that they were much older, it was much too much for her to handle. When this need was identified, in stepped P3, utilizing our social workers and administrative team to ensure that her husband could get the right care in the right place. Dr. Powell knew he didn't want the patient to necessarily have to go to the hospital and then be transferred to a rehab facility, the typical avenue to get an admission into a rehab hospital. Instead, we at P3 were able to find an assisted living facility that could manage the patient's rehab needs while also giving his wife peace of mind for her husband's ongoing care. At P3, we understand that by focusing on what care really means, it's not just about doing a procedure or adding medications. Sometimes the most important and impactful care is engaging and ensuring the appropriate navigation of a complex system to take care of one's needs. Doing the right thing more often than not leads to a win-win for both provider and the patient and is usually accompanied by a significant reduction in cost, just as in this case. Also in Dr. Powell's video, he went on to explain how P3 aligns its incentives for providers to encourage them to take the time to complete a thorough comprehensive exam to understand the entirety of a patient's condition, something that traditional Medicare does not pay for today. This is something that P3 insists is done for each patient each year to ensure that we understand how to help best manage those with chronic conditions as their needs change and potentially worsen over time. This in turn allows P3 to know which patients require more services and specialty care so that we can support them as best possible. Our core value is to keep patients as happy and healthy as possible, improving the overall health of our patients, improve satisfaction, and decreases costs so that everyone wins, including you, our shareholders. I would encourage you to listen to Dr. Tim Powell directly on YouTube in his own words. We have made it available on our IR webpage. Thank you. Now I will turn it back over to Sherif Abdou. Thanks, Amir. Before we start and begin our Q&A, I will leave you with this. As I started with, we're reporting a very strong third quarter and a strong underlying performance from our medical management team. The net rate and membership increase YoY, same period, 67%. A YoY revenue improvement of approximately 60% and roughly 180 basis point improvement in our gross profit. Our base cohort, which has about 9,000 lives in it, continue to show a consistent 11% average annual improvement in the medical cost. That cohort or the life that's been with us for 36+ months. The PMPM EBITDA, as Erin had discussed, if you compare year to date EBITDA with the first three months in 2021, there's a 6.5% improvement approximately. Even if you compare end of year 2021 EBITDA and you compare the new guidance, it still reflects about 11%-22% improvement, as Erin had discussed. We continue to see a robust demand and a robust pipeline for the growth in 2023 and beyond. We're executing on our disciplined, purposeful growth strategy, which focuses not only on growth, but prudent management of the balance sheet. Thank you. Now, Victoria, we'll be happy to take any questions. Thank you. We will now be conducting a Q&A session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. Please, if you want to remove yourself from the question queue, you may press star two. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the keys. One moment, please, while we pull for questions. Our first question comes from Joshua Raskin with Nephron Research. Please go ahead. Josh, the floor is yours. Hi, can you hear me? Yes, we can. Hello? Oh, okay. Great. Thanks. Sorry about that. I wanted to ask about the EBITDA guidance, you know, down about $51 million or so. I'm only counting, I think $39 million of items that were called out, that Erin went through. Was there some operational change or am I doing the math wrong? I just wanna make sure, 'cause I think, Dr. Abdou, you talked about no change to the operation. I just wanna make sure that I'm not missing something there. Yeah, no, Josh, thank you very much for the question and clarification. It's the cost of care that's not related to the claim related is what increased with the membership. For example, we pay extra amount for a comprehensive visit examination, and last year we paid for 60,000 lives. This year, we're paying for over 100,000 lives. That would increase. Even though it's not a medical cost, your medical management does not include, but it's a cost of, you can call it operation or you can call it cost of sales or cost of goods, standard language. I appreciate you pointing that out. It's all related to the cost increase in membership. Okay. It's the $12 million for the final settlement sweep. It's the, you know, $7 million-$12 million, which let's call $10 million, you know, additional resources for the audit and then the $15 million-$20 million that gets kicked into 2023. Then the increment is, from your previous guidance, is the incremental cost of these, you know, say, doing these comprehensive visits for 40,000 more lives. That's the idea? That's the idea. Thank you. Okay. Starting, you know, the, I guess sort of an outlook for 2023, I understand you're not gonna give guidance, but I just have a couple of moving parts. Did I hear Erin say that the EBITDA loss would be $34 million-$42 million in 2022? Is that a reasonable baseline to start? Is that the starting point? I'm sorry, Josh. You're saying for full year 2022? The full year EBITDA loss guidance? Yeah. Well, for 2022, right, excluding these kind of what we would, you would describe as one-time items, what's like the right baseline? Yep. Gotcha. Yeah. We're saying the three that you just mentioned, if you added those back, it would be an improvement of around $34 million-$42 million. In line with our prior guidance of around $90 million. Yes. All right. It was sort of 55-90. I'm sorry to be so specific on this, but the 118-128, add back 34-42, that's the baseline. That's the first, that's the starting point. Then second, you know, I know at the time of the SPAC, it's a long time ago, but you guys were looking for 2023 revenues of about a, you know, $1.25 billion or a $1.255 billion. You know, in light of the outperformance, significant outperformance for 2022, maybe you could just give us some directional feedback on revenues for next year, if there's any kind of, like, one-time big contract wins or if it's just sort of the expected, you know, continuation of your sort of, you know, what I'll call normal growth. Then again, if you could just give us some color on, I know EBITDA breakeven in 2024, but does 2023 look more like 2022, or does it, you know, does it get you halfway there? Just some sense of where you're headed, you know, so that we can sort of figure out sort of cash needs. Josh, I really appreciate that question. You know, our lawyer will be chopping my head if I start getting into 2023. You're the master of expectations, so I let everybody kind of reread what you just said, but I have no comments to give on 2023 guidance at this point. That's fair. Excited, but no specifics. Okay. That's fair. I'll get back in queue if I've got others. Next question comes from Brooks O'Neil with Lake Street. Please go ahead. Thank you. Good afternoon, everyone. I have a couple questions too. I'm gonna try not to be quite as mathematical as Josh was, but let me just start off by saying, when I look at your balance sheet for September 30th, I see roughly $35 million in cash, and obviously you've got $80 million of debt. In light of the report today and kind of the outlook for the fourth quarter and into 2023, how should we think about the kind of capital you believe you need to get through 2023 and get to 2024 to the Adjusted EBITDA breakeven level you're talking about? Hi, Brooks O'Neil. This is Erin Darakjian. Thank you for that question. I'll just reiterate, you know, our strong growth has contributed to the cash burn that you're seeing. We're very focused on being prudent regarding cash, and we're in active discussions to ensure liquidity. We have highly supportive shareholders of the company that are very big believers in the P3 model. We're also actively looking at options and in discussions with our board and active market players on potentially refinancing or enlarging that debt facility. Okay. I understand all that. Let me ask a somewhat different question. It feels to me, in the current environment as I talk to healthcare players around the country, like you have virtually unlimited opportunity to add membership, that the marketplace needs you and the model you bring to the party. My question is: How do you guys think about balancing growth, membership growth, let's say, with the obvious reality that the more members you take, the more money you'll lose? Brooks, thank you very much for the question. But more importantly, thank you for the observation that we've always, as we reported, excited about having been in the right space, which is the Medicare Advantage, with the right model, which is the affiliated delegated model, with definitely the right team being Dr. Bacchus, Laurie, Sarah, and Erin and all the great leaders that we have in the space. As I mentioned repeatedly in my presentation, we continue to focus on the disciplined, purposeful growth. We're able to get our strategy and our pipeline focus, for example, on the counties that we're in. We'll go deeper in the county by increasing providers and payers in the same county, and hence leveraging our platform and allowing us to grow without the exponential costs or losses that it was before. Second, we are looking into a strategic relationship with other providers in the marketplace where we can improve on our unit cost while we are growing our membership. As we mature into the model and as the demand goes up, we're more disciplined, more purposeful, but also more powerful in our ability to manage the unit cost as well as manage the overall cost. Great. Let me just ask one more. I appreciate that, Sherif. That was very helpful. Recognize that 2021 and 2022 have been characterized by not only the disruption of the audit and all of that, but COVID and staffing and all those things. I'm just would love to get your perspective as you sit today and as you think about, let's say, the next year, and I'm not asking for guidance, I'm asking for what, how do you evaluate the biggest challenges you face in the environment you see out there now and what you anticipate as we move into the new year? Great question. Let me divide that into two ways. One is how do I look to 2023 in comparing to 2022 and 2021. Number one, we've been talking about the cohort of the lives that is in a club that is 36+ months on our platform. This cohort is gonna double in 2023. Naturally, there will be improvement in overall population on this cohort and their health outcome and their cost overall. Number two, the labor market continued to represent a challenge, definitely in 2021, definitely in 2022. We think that we either reach a peak and a plateau or it might soften a little bit. I think we will, we anticipate those kind of challenges to ease up a little bit. The demand will be great, and we're gonna have to have the discipline to do two things. One, stay and go deep in the counties that we're already in. Two, pick the right partner with the ability to move lives through a glide path to risk rather than doing the risk immediately. We continue to find and refine our growth model, and that will shape 2023. Perfect. Thank you very much. I'm excited for the new year. Thank you, sir. Next question comes from Gary Taylor with Cowen. Please go ahead. Hi, good afternoon. I guess I wanted to, you know, if we look at the third quarter medical loss ratio, excluding the PDR benefit, it's 104%. I know you're describing that as a strong quarter, even though it's well above some initial expectations. I guess there's so much focus on the revenue line as being strong and less on the medical expense line. Can you give us some insight or data to help us understand how those cohorts are developing and whether or not your new contracts or all your new contracts are running above 100% MLR? Great question, Gary, and I appreciate that as always. As far as the details, let me gather them, and I will. I promise that I will share them with you in detail. I don't have it right in front of me, and I don't wanna give you an answer that's not completely accurate. Let me explain one thing. It's when we talk about the medical loss ratio, and we internally discussing the way that we purify that to be consistent with our peers' reporting, the medical loss, as we report it, include a lot of non-claims related third-party providers. A lot of activity included in the cost of care that's not in the medical loss ratio, that's not traditionally in the claims. For example, any surplus that we redistribute to the providers, we added there. Any extra incentive for quality or access, we pay to the medical groups, we added there. It's not related to the cost of care, but it's related to the cost of operation. I promise you that I will get the details on the cohort, the details of that medical cost, so you can share my excitement of the improvement in the performance, underlying performance of our medical management team. Okay. Just moving to Erin, I just wanna make sure I understand this $15-$20 million of revenue that was in the guidance for 2022 that's now moving into 2023. Is that risk coding revenue. You saw the patient in 2021, you coded them in 2021. You're receiving that revenue from the plan in 2022, but you're not gonna capture this last piece of that revenue until the sweeps are done in 2023? Am I understanding that correctly, or can you clarify how that revenue is moving? The revenue that's the $15-$20 million is actually related to services that were in 2022. Mm-hmm. That will be recognized in 2023. It's not 2021. It's 2022 services that we will recognize when we receive the revenue in 2023. You're seeing the patient this year, you're coding them this year, but that's gonna be reflected in their risk-adjusted revenue next year. That's correct. Why is that moving if you're not changing your revenue recognition practice? 'Cause I think industry convention has been, you recognize the revenue in the year that you expect the plan to pass that risk coding revenue on to you. We recognize the mid-year adjustment in this current year, but we recognize the final settlement in the next year when we receive it. That's based on cash basis. Right. That's been your policy. Why is that moving? I thought you said the revenue recognition didn't change, so I'm not sure I understood why the revenue moves from 2022 to 2023. Due to the length of our 2021 audit, we had to push back those final settlements into 2021 that we would have otherwise recognized in 2022. We looked at the possibility that we would move it into this year as well. After consulting with our auditors and outside consultants, we decided to keep our existing policy of our revenue recognition and recognize it into next year. Okay. Last one for me. The queue talks about your largest payer being 19% of revenue, but 35% of receivables. Is there any, like, easy, quick explanation as to why that is, why that cycle is running longer with that largest payer? That's a great question. I'll have to look into it and get back to you on it, but I'll take a note and we'll make sure Karen reaches out to you with that answer. Okay. Thank you. The next question comes from Ryan Daniels with William Blair. Please go ahead. Hey, guys. This is Jackson on for Ryan Daniels. Thanks for taking my question. First off, can you just elaborate more on the details of the $15 million-$20 million in sweeps? And then just as a second part, this is just going off of I think it was Josh Raskin's line of questioning on the guidance numbers, specifically within the delta. I'm just kind of curious, has anything changed between the previous release and now? You know, and is there anything further to kind of call out, besides the sweeps that could impact, you know, fourth quarter as well? Thanks for that question, Jackson. Like we said, you know, we did consult with our auditors and consultants. We were looking into the possibility of, you know, having our 2022 sweeps reflected in 2022, but we ended up pushing it, like we said, to keep our existing policy and recognizing that revenue in 2023. You know, as we said before, we pushed $12 million back into 2021, and we incurred another $7 million-$10 million in non-recurring costs related to the length of the audit, as well as, you know, restatement, the restatement process that we've just completed, yeah, less than a month ago, three weeks ago here. Thanks. Then just looking at the corporate G&A line item, it still seems slightly elevated compared to the previous year, even though it was down on a sequential basis. Can you provide any additional color on how we should think about this into the fourth quarter and then possibly into next year as well? Thanks. As I said before, we had some one-time items, you know, totaling $7 million-$10 million. Now we're through that restatement process, we deem these to be non-recurring. Okay. Awesome. Thanks. Just the last thing that I have, are there any investments or anything on the M&A side that you might look into or even have identified to help supplement your growth into 2023? Jackson, this is Sherif. It's great question. Here in Henderson, in the market that we're in, we're laser focused on, in the management team overall, on the improvement in operational excellence, improving our balance sheet, improving our medical costs, improving the health of our patients day in, day out. We have a lot of consultants and the board that look into all these opportunities. I'm sure they will let us know as soon as anything become meaningful for discussion. There are no further questions at this time. I would like to turn the floor back over to Dr. Sherif Abdou for closing comments. Thank you very much, Victoria, and thanks everyone. Really appreciate the question, Josh, Brooks, Jackson, and Gary, for sure. I owe you to return with the details on the cohort and other question that you had. I wanna close by reminding you that even though we're lowering our EBITDA guidance today, it's an improvement of 11%-22% per member per month, which is how any population health management should measure itself YoY. I wanna remind you that we have enjoyed 60%+ increase in revenue, 67% increase in membership, and 176 to almost 180 basis points improvement in gross profit. We continue to be excited about the pipeline and the demand that we are witnessing in 2023 and beyond. With that, I wanna thank you all for your interest and participation today, and I look forward to our next call soon. That is gonna be on schedule, on time, and on the same compliant cadence. Thank you very much. Have a great evening, everyone. This concludes today's teleconference. You may disconnect your line at this time. Thank you for your participation.